The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Open accessAbstract
Cyclic dinucleotides (CDNs) are agonists of stimulator of IFN genes (STING) and have potential as vaccine adjuvants. However, cyclic di-GMP (cdGMP) injected s.c. shows minimal uptake into lymphatics/draining lymph nodes (dLNs) and instead is rapidly distributed to the bloodstream, leading to systemic inflammation. Here, we encapsulated cdGMP within PEGylated lipid nanoparticles (NP-cdGMP) to redirect this adjuvant to dLNs. Compared with unformulated CDNs, encapsulation blocked systemic dissemination and markedly enhanced dLN accumulation in murine models. Delivery of NP-cdGMP increased CD8+ T cell responses primed by peptide vaccines and enhanced therapeutic antitumor immunity. A combination of a poorly immunogenic liposomal HIV gp41 peptide antigen and NP-cdGMP robustly induced type I IFN in dLNs, induced a greater expansion of vaccine-specific CD4+ T cells, and greatly increased germinal center B cell differentiation in dLNs compared with a combination of liposomal HIV gp41 and soluble CDN. Further, NP-cdGMP promoted durable antibody titers that were substantially higher than those promoted by the well-studied TLR agonist monophosphoryl lipid A and comparable to a much larger dose of unformulated cdGMP, without the systemic toxicity of the latter. These results demonstrate that nanoparticulate delivery safely targets CDNs to the dLNs and enhances the efficacy of this adjuvant. Moreover, this approach can be broadly applied to other small-molecule immunomodulators of interest for vaccines and immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Follicular Helper CD4 T Cells (T FH )
Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1229963 · Cited by 2,541
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A., & Colonna, M. (1999) · Nature Medicine · doi:10.1038/11360 · Cited by 1,737
Cyclic di-GMP: the First 25 Years of a Universal Bacterial Second Messenger
Römling, U., Galperin, M. Y., & Gomelsky, M. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00043-12 · Cited by 1,700
CGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695
STING is a direct innate immune sensor of cyclic di-GMP
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Pasparakis, M., Alexopoulou, L., Episkopou, V, & Kollias, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1397 · Cited by 1,160
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., & Lanzavecchia, A. (2005) · Nature Immunology · doi:10.1038/ni1223 · Cited by 1,157
Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects
Li, X.-D., Wu, J., Gao, D., Wang, H., Sun, L., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1244040 · Cited by 1,113
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., & Tough, D. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00126-1 · Cited by 974
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Self-citationWoodward, J. J., Iavarone, A. T., & Portnoy, D. A. (2010) · Science · doi:10.1126/science.1189801 · Cited by 810
Persistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755
Liposomes for the sustained drug release in vivo
Blume, G., & Cevc, G. (1990) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(90)90440-y · Cited by 698
Spörri, R., & Reis e Sousa, C. (2005) · Nature Immunology · doi:10.1038/ni1162 · Cited by 626
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Self-citationMoon, J. J., Suh, H., Bershteyn, A., Stephan, M. T., Liu, H., Huang, B., Sohail, M., Luo, S., Ho Um, S., Khant, H., et al. (2011) · Nature Materials · doi:10.1038/nmat2960 · Cited by 564
Self-citationSauer, J.-D., Sotelo-Troha, K., von Moltke, J., Monroe, K. M., Rae, C. S., Brubaker, S. W., Hyodo, M., Hayakawa, Y., Woodward, J. J., Portnoy, D. A., et al. (2011) · Infection and Immunity · doi:10.1128/iai.00999-10 · Cited by 539
The RTS, S. C. T. P. (. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001685 · Cited by 474
Vaccines for the twenty-first century society
Rappuoli, R., Mandl, C. W., Black, S., & De Gregorio, E. (2011) · Nature Reviews Immunology · doi:10.1038/nri3085 · Cited by 388
Le Bon, A., Thompson, C., Kamphuis, E., Durand, V., Rossmann, C., Kalinke, U., & Tough, D. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2074 · Cited by 361
Asselin-Paturel, C., Brizard, G., Pin, J.-J., Brière, F., & Trinchieri, G. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6466 · Cited by 360
Ouyang, S., Song, X., Wang, Y., Ru, H., Shaw, N., Jiang, Y., Niu, F., Zhu, Y., Qiu, W., Parvatiyar, K., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.019 · Cited by 350
A novel Ly6C/Ly6G‐based strategy to analyze the mouse splenic myeloid compartment
Rose, S., Misharin, A., & Perlman, H. (2012) · Cytometry Part A · doi:10.1002/cyto.a.22012 · Cited by 347
Wille-Reece, U., Flynn, B. J., Loré, K., Koup, R. A., Kedl, R. M., Mattapallil, J. J., Weiss, W. R., Roederer, M., & Seder, R. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507484102 · Cited by 332
Immunity in response to particulate antigen-delivery systems
STORNI, T., KUNDIG, T., SENTI, G., & JOHANSEN, P. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.09.008 · Cited by 317
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Moon, J. J., Suh, H., Li, A. V., Ockenhouse, C. F., Yadava, A., & Irvine, D. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112648109 · Cited by 312
Self-citationShu, C., Yi, G., Watts, T., Kao, C. C., & Li, P. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2331 · Cited by 305
Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype
Demento, S. L., Cui, W., Criscione, J. M., Stern, E., Tulipan, J., Kaech, S. M., & Fahmy, T. M. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.041 · Cited by 304
McWhirter, S. M., Barbalat, R., Monroe, K. M., Fontana, M. F., Hyodo, M., Joncker, N. T., Ishii, K. J., Akira, S., Colonna, M., Chen, Z. J., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082874 · Cited by 296
Accelerating Next-Generation Vaccine Development for Global Disease Prevention
Koff, W. C., Burton, D. R., Johnson, P. R., Walker, B. D., King, C. R., Nabel, G. J., Ahmed, R., Bhan, M. K., & Plotkin, S. A. (2013) · Science · doi:10.1126/science.1232910 · Cited by 282
Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J.-P., Haddad, E. K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111171 · Cited by 271
Subcutaneous drug delivery and the role of the lymphatics
McLennan, D. N., Porter, C. J. H., & Charman, S. A. (2005) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2005.05.006 · Cited by 259 · cited 1×
“This biodistribution issue is a property of molecular size: because blood absorbs approximately 10-fold more fluid from tissues than lymph, molecules small enough to permeate blood vessels (less than ~1 kDa) tend to show predominant clearance to the blood (69).”
de Titta, A., Ballester, M., Julier, Z., Nembrini, C., Jeanbart, L., van der Vlies, A. J., Swartz, M. A., & Hubbell, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313152110 · Cited by 254
Montero, M., van Houten, N. E., Wang, X., & Scott, J. K. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00020-07 · Cited by 253
Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles
Cai, S., Yang, Q., Bagby, T. R., & Forrest, M. L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.017 · Cited by 252
Fletcher, A. L., Malhotra, D., Acton, S. E., Lukacs-Kornek, V., Bellemare-Pelletier, A., Curry, M., Armant, M., & Turley, S. J. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00035 · Cited by 249
Jewell, C. M., Bustamante López, S. C., & Irvine, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105200108 · Cited by 245
Self-citationWaterhouse, D. N., Tardi, P. G., Mayer, L. D., & Bally, M. B. (2001) · Drug Safety · doi:10.2165/00002018-200124120-00004 · Cited by 242
Barker, J. R., Koestler, B. J., Carpenter, V. K., Burdette, D. L., Waters, C. M., Vance, R. E., & Valdivia, R. H. (2013) · mBio · doi:10.1128/mbio.00018-13 · Cited by 234
STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Chandra, D., Quispe-Tintaya, W., Jahangir, A., Asafu-Adjei, D., Ramos, I., Sintim, H. O., Zhou, J., Hayakawa, Y., Karaolis, D. K. R., & Gravekamp, C. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0123 · Cited by 231
Bacterial c-di-GMP Is an Immunostimulatory Molecule
Karaolis, D. K. R., Means, T. K., Yang, D., Takahashi, M., Yoshimura, T., Muraille, E., Philpott, D., Schroeder, J. T., Hyodo, M., Hayakawa, Y., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2171 · Cited by 222
Cucak, H., Yrlid, U., Reizis, B., Kalinke, U., & Johansson-Lindbom, B. (2009) · Immunity · doi:10.1016/j.immuni.2009.07.005 · Cited by 202
Simon, A., Park, H., Maddipati, R., Lobito, A. A., Bulua, A. C., Jackson, A. J., Chae, J. J., Ettinger, R., de Koning, H. D., Cruz, A. C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914118107 · Cited by 196
Dubensky, T. W., Kanne, D. B., & Leong, M. L. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613501988 · Cited by 175
Smirnov, D., Schmidt, J. J., Capecchi, J. T., & Wightman, P. D. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.061 · Cited by 174
Recent progress concerning CpG DNA and its use as a vaccine adjuvant
Shirota, H., & Klinman, D. M. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.863715 · Cited by 172
Ilyinskii, P. O., Roy, C. J., O’Neil, C. P., Browning, E. A., Pittet, L. A., Altreuter, D. H., Alexis, F., Tonti, E., Shi, J., Basto, P. A., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.027 · Cited by 171
A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy
Miyabe, H., Hyodo, M., Nakamura, T., Sato, Y., Hayakawa, Y., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.004 · Cited by 163
Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo
Swiecki, M. K., Wang, Y., Vermi, W., Gilfillan, S., Schreiber, R. D., & Colonna, M. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110654 · Cited by 161
Tewari, K., Flynn, B., Boscardin, S., Kastenmueller, K., Salazar, A., Anderson, C., Soundarapandian, V., Ahumada, A., Keler, T., Hoffman, S., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.098 · Cited by 153
A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
Coler, R. N., Baldwin, S. L., Shaverdian, N., Bertholet, S., Reed, J., Raman, V. S., Lu, X., DeVos, J. R., Hancock, K., Katz, J. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013677 · Cited by 150
Garaude, J., Kent, A., van Rooijen, N., & Blander, J. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002868 · Cited by 147
Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant
Ebensen, T., Libanova, R., Schulze, K., Yevsa, T., Morr, M., & Guzmán, C. A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.026 · Cited by 137
Behzad, H., Huckriede, A. L. W., Haynes, L., Gentleman, B., Coyle, K. M., Wilschut, J., Kollmann, T. R., Reed, S. G., & McElhaney, J. E. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir769 · Cited by 135
Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction
Desch, A. N., Gibbings, S. L., Clambey, E. T., Janssen, W. J., Slansky, J. E., Kedl, R. M., Henson, P. M., & Jakubzick, C. (2014) · Nature Communications · doi:10.1038/ncomms5674 · Cited by 132
Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine
Bershteyn, A., Hanson, M. C., Crespo, M. P., Moon, J. J., Li, A. V., Suh, H., & Irvine, D. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.029 · Cited by 118
Self-citationDose Sparing of CpG Oligodeoxynucleotide Vaccine Adjuvants by Nanoparticle Delivery
Diwan, M., Elamanchili, P., Cao, M., & Samuel, J. (2004) · Current Drug Delivery · doi:10.2174/1567201043334597 · Cited by 118
Xie, H., Gürsel, İ., Ivins, B. E., Singh, M., O’Hagan, D. T., Ulmer, J. B., & Klinman, D. M. (2005) · Infection and Immunity · doi:10.1128/iai.73.2.828-833.2005 · Cited by 109
Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand
Wu, C. C. N., Hayashi, T., Takabayashi, K., Sabet, M., Smee, D. F., Guiney, D. D., Cottam, H. B., & Carson, D. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611624104 · Cited by 106
Oussoren, C., & Storm, G. (1997) · Pharmaceutical Research · doi:10.1023/a:1012145410859 · Cited by 102
Madhun, A. S., Haaheim, L. R., Nøstbakken, J. K., Ebensen, T., Chichester, J. A., Yusibov, V. M., Guzmán, C. A., & Cox, R. J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.094 · Cited by 102
Parent, M. A., Wilhelm, L. B., Kummer, L. W., Szaba, F. M., Mullarky, I. K., & Smiley, S. T. (2006) · Infection and Immunity · doi:10.1128/iai.00185-06 · Cited by 100
van Stipdonk, M. J. B., Badia-Martinez, D., Sluijter, M., Offringa, R., van Hall, T., & Achour, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1724 · Cited by 92
The potential of 3′,5′-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant
Chen, W., KuoLee, R., & Yan, H. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.02.081 · Cited by 88
The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties
Ebensen, T., Schulze, K., Riese, P., Link, C., Morr, M., & Guzmán, C. A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.033 · Cited by 84
Kulkarni, R. R., Rasheed, M. A. U., Bhaumik, S. K., Ranjan, P., Cao, W., Davis, C. W., Marisetti, K., Thomas, S., Gangappa, S., Sambhara, S. R., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02273-14 · Cited by 83
c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection
Ogunniyi, A. D., Paton, J. C., Kirby, A. C., McCullers, J. A., Cook, J., Hyodo, M., Hayakawa, Y., & Karaolis, D. K. R. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.099 · Cited by 80
Harrison, L. I., Astry, C. L., Kumar, S., & Yunis, C. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303766 · Cited by 80
Hu, D., Narita, K., Hyodo, M., Hayakawa, Y., Nakane, A., & Karaolis, D. K. R. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.053 · Cited by 73
Blaauboer, S. M., Gabrielle, V. D., & Jin, L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301812 · Cited by 73
Structure-Informed Design of an Enzymatically Inactive Vaccine Component for Group A Streptococcus
Henningham, A., Ericsson, D. J., Langer, K., Casey, L. W., Jovcevski, B., Chhatwal, G. S., Aquilina, J. A., Batzloff, M. R., Kobe, B., & Walker, M. J. (2013) · mBio · doi:10.1128/mbio.00509-13 · Cited by 71
The Bacterial Second Messenger cdiGMP Exhibits Promising Activity as a Mucosal Adjuvant
Ebensen, T., Schulze, K., Riese, P., Morr, M., & Guzmán, C. A. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00119-07 · Cited by 68
Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities
Gray, P. M., Forrest, G., Wısnıewskı, T., Porter, G., Freed, D. C., DeMartino, J. A., Zaller, D. M., Guo, Z., Leone, J. W., Fu, T., et al. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.006 · Cited by 63
Park, H., Adamson, L., Ha, T., Mullen, K., Hagen, S. I., Nogueron, A., Sylwester, A. W., Axthelm, M. K., Legasse, A., Piatak, M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202958 · Cited by 58
Libanova, R., Ebensen, T., Schulze, K., Bruhn, D., Nörder, M., Yevsa, T., Morr, M., & Guzmán, C. A. (2010) · Vaccine · doi:10.1016/j.vaccine.2009.12.045 · Cited by 54
3′,5′-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection
Yan, H., KuoLee, R., Tram, K., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.061 · Cited by 53
Pihlgren, M., Silva, A. B., Madani, R., Giriens, V., Waeckerle‐Men, Y., Fettelschoss‐Gabriel, A., Hickman, D. T., López-Deber, M. P., Ndao, D. M., Vukicevic, M., et al. (2012) · Blood · doi:10.1182/blood-2012-02-413831 · Cited by 45
Kim, M., Song, L., Moon, J. J., Sun, Z.-Y. J., Bershteyn, A., Hanson, M. C., Cain, D. W., Goka, S. Q., Kelsoe, G. H., Wagner, G., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494609 · Cited by 44
Self-citationCyclic di‐nucleotides: new era for small molecules as adjuvants
Libanova, R., Becker, P. D., & Guzmán, C. A. (2011) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2011.00306.x · Cited by 42
Targeting HIV-1 gp41 in Close Proximity to the Membrane Using Antibody and Other Molecules
Gach, J. S., Leaman, D. P., & Zwick, M. B. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611798808505 · Cited by 28
Cited by
The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293
“Innovative approaches, such as nanoparticles (Hanson et al., 2015; Luo et al., 2017; Wilson et al., 2018), viral particles (Bridgeman et al.”
BackgroundRethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Self-citationShae, D., Becker, K. W., Christov, P., Yun, D. S., Lytton-Jean, A. K. R., Sevimli, S., Ascano, M., Kelley, M., Johnson, D. B., Balko, J. M., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0342-5 · Cited by 668
Metadata
- Authors
- Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-05-04
- Volume
- 125
- Issue
- 6
- Pages
- 2532-2546
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2169908694
- Cited by
- 381
- References
- 88
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.